Drug Manufacturers - Specialty & Generic
Compare Stocks
4 / 10Stock Comparison
EBS vs BRKR vs WAT vs SIGA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Diagnostics & Research
Drug Manufacturers - Specialty & Generic
EBS vs BRKR vs WAT vs SIGA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Devices | Medical - Diagnostics & Research | Drug Manufacturers - Specialty & Generic |
| Market Cap | $472M | $6.66B | $22.83B | $339M |
| Revenue (TTM) | $743M | $3.46B | $3.77B | $94M |
| Net Income (TTM) | $53M | $-12M | $449M | $-4.04T |
| Gross Margin | 47.1% | 45.3% | 55.0% | 61.8% |
| Operating Margin | 14.7% | 4.9% | 17.1% | 27.7% |
| Forward P/E | 17.6x | 20.7x | 24.4x | 2.8x |
| Total Debt | $572M | $2.04B | $1.41B | $595K |
| Cash & Equiv. | $205M | $299M | $588M | $155M |
EBS vs BRKR vs WAT vs SIGA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Emergent BioSolutio… (EBS) | 100 | 10.9 | -89.1% |
| Bruker Corporation (BRKR) | 100 | 101.0 | +1.0% |
| Waters Corporation (WAT) | 100 | 175.3 | +75.3% |
| SIGA Technologies, … (SIGA) | 100 | 79.0 | -21.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EBS vs BRKR vs WAT vs SIGA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EBS is the clearest fit if your priority is momentum.
- +92.7% vs WAT's +1.4%
BRKR lags the leaders in this set but could rank higher in a more targeted comparison.
WAT carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 7.0%, EPS growth 0.5%, 3Y rev CAGR 2.1%
- 7.0% revenue growth vs SIGA's -31.8%
- 11.9% margin vs SIGA's -43K%
- Beta 1.07 vs EBS's 1.83, lower leverage
SIGA is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- 7.6% 10Y total return vs WAT's 162.0%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
- Beta 1.15, yield 12.7%, current ratio 11.83x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.0% revenue growth vs SIGA's -31.8% | |
| Value | Lower P/E (2.8x vs 24.4x) | |
| Quality / Margins | 11.9% margin vs SIGA's -43K% | |
| Stability / Safety | Beta 1.07 vs EBS's 1.83, lower leverage | |
| Dividends | 12.7% yield, 4-year raise streak, vs BRKR's 0.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +92.7% vs WAT's +1.4% | |
| Efficiency (ROA) | 4.6% ROA vs SIGA's -7.4%, ROIC 20.3% vs 33.7% |
EBS vs BRKR vs WAT vs SIGA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EBS vs BRKR vs WAT vs SIGA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SIGA leads in 4 of 6 categories
EBS leads 1 • WAT leads 1 • BRKR leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
SIGA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
WAT is the larger business by revenue, generating $3.8B annually — 40.2x SIGA's $94M. WAT is the more profitable business, keeping 11.9% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $743M | $3.5B | $3.8B | $94M |
| EBITDAEarnings before interest/tax | $207M | $397M | $953M | $26M |
| Net IncomeAfter-tax profit | $53M | -$12M | $449M | -$4.04T |
| Free Cash FlowCash after capex | $157M | $51M | $264M | $33M |
| Gross MarginGross profit ÷ Revenue | +47.1% | +45.3% | +55.0% | +61.8% |
| Operating MarginEBIT ÷ Revenue | +14.7% | +4.9% | +17.1% | +27.7% |
| Net MarginNet income ÷ Revenue | +7.1% | -0.3% | +11.9% | -43117.4% |
| FCF MarginFCF ÷ Revenue | +21.1% | +1.5% | +7.0% | +35.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | +2.7% | +91.5% | -11.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -76.3% | -79.2% | -142.9% | — |
Valuation Metrics
EBS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 9.8x trailing earnings, EBS trades at a 70% valuation discount to WAT's 32.6x P/E. On an enterprise value basis, EBS's 4.0x EV/EBITDA is more attractive than WAT's 21.5x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $472M | $6.7B | $22.8B | $339M |
| Enterprise ValueMkt cap + debt − cash | $838M | $8.4B | $23.7B | $185M |
| Trailing P/EPrice ÷ TTM EPS | 9.82x | -291.53x | 32.55x | 14.33x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.57x | 20.68x | 24.36x | 2.78x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.29x | — |
| EV / EBITDAEnterprise value multiple | 4.02x | 18.41x | 21.51x | 7.60x |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 1.94x | 7.21x | 3.58x |
| Price / BookPrice ÷ Book value/share | 0.99x | 2.64x | 8.17x | 1.70x |
| Price / FCFMarket cap ÷ FCF | 3.01x | 153.73x | 42.30x | 6.96x |
Profitability & Efficiency
SIGA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
EBS delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-11 for SIGA. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to EBS's 1.09x. On the Piotroski fundamental quality scale (0–9), EBS scores 7/9 vs WAT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.6% | -0.5% | +8.0% | -10.7% |
| ROA (TTM)Return on assets | +3.7% | -0.2% | +4.6% | -7.4% |
| ROICReturn on invested capital | +8.5% | +4.4% | +20.3% | +33.7% |
| ROCEReturn on capital employed | +9.1% | +5.0% | +18.5% | +11.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | 1.09x | 0.81x | 0.55x | 0.00x |
| Net DebtTotal debt minus cash | $367M | $1.7B | $820M | -$154M |
| Cash & Equiv.Liquid assets | $205M | $299M | $588M | $155M |
| Total DebtShort + long-term debt | $572M | $2.0B | $1.4B | $595,169 |
| Interest CoverageEBIT ÷ Interest expense | 1.84x | 1.14x | 6.72x | — |
Total Returns (Dividends Reinvested)
SIGA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WAT five years ago would be worth $11,133 today (with dividends reinvested), compared to $1,482 for EBS. Over the past 12 months, EBS leads with a +92.7% total return vs WAT's +1.4%. The 3-year compound annual growth rate (CAGR) favors SIGA at 6.9% vs BRKR's -16.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.0% | -9.0% | -8.3% | -15.0% |
| 1-Year ReturnPast 12 months | +92.7% | +7.8% | +1.4% | +1.5% |
| 3-Year ReturnCumulative with dividends | +0.2% | -42.5% | +18.1% | +22.2% |
| 5-Year ReturnCumulative with dividends | -85.2% | -35.5% | +11.3% | +1.4% |
| 10-Year ReturnCumulative with dividends | -76.6% | +67.1% | +162.0% | +764.0% |
| CAGR (3Y)Annualised 3-year return | +0.1% | -16.9% | +5.7% | +6.9% |
Risk & Volatility
WAT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
WAT is the less volatile stock with a 1.07 beta — it tends to amplify market swings less than EBS's 1.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WAT currently trades 84.6% from its 52-week high vs SIGA's 49.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.83x | 1.59x | 1.07x | 1.15x |
| 52-Week HighHighest price in past year | $14.06 | $56.22 | $414.15 | $9.62 |
| 52-Week LowLowest price in past year | $4.72 | $28.53 | $275.05 | $4.29 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +77.8% | +84.6% | +49.2% |
| RSI (14)Momentum oscillator 0–100 | 61.4 | 64.8 | 64.9 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 873K | 1.9M | 999K | 688K |
Analyst Outlook
SIGA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EBS as "Buy", BRKR as "Buy", WAT as "Hold", SIGA as "Buy". Consensus price targets imply 31.4% upside for EBS (target: $12) vs 14.9% for WAT (target: $403). For income investors, SIGA offers the higher dividend yield at 12.73% vs BRKR's 0.34%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $12.00 | $52.13 | $402.57 | — |
| # AnalystsCovering analysts | 15 | 32 | 34 | 1 |
| Dividend YieldAnnual dividend ÷ price | — | +0.3% | — | +12.7% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 1 | 4 |
| Dividend / ShareAnnual DPS | — | $0.15 | — | $0.60 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.3% | +0.2% | +0.1% | 0.0% |
SIGA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EBS leads in 1 (Valuation Metrics).
EBS vs BRKR vs WAT vs SIGA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EBS or BRKR or WAT or SIGA a better buy right now?
For growth investors, Waters Corporation (WAT) is the stronger pick with 7.
0% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). Emergent BioSolutions Inc. (EBS) offers the better valuation at 9. 8x trailing P/E (17. 6x forward), making it the more compelling value choice. Analysts rate Emergent BioSolutions Inc. (EBS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EBS or BRKR or WAT or SIGA?
On trailing P/E, Emergent BioSolutions Inc.
(EBS) is the cheapest at 9. 8x versus Waters Corporation at 32. 6x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — EBS or BRKR or WAT or SIGA?
Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.
3%, compared to -85. 2% for Emergent BioSolutions Inc. (EBS). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus EBS's -76. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EBS or BRKR or WAT or SIGA?
By beta (market sensitivity over 5 years), Waters Corporation (WAT) is the lower-risk stock at 1.
07β versus Emergent BioSolutions Inc. 's 1. 83β — meaning EBS is approximately 71% more volatile than WAT relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 109% for Emergent BioSolutions Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EBS or BRKR or WAT or SIGA?
By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.
0% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Emergent BioSolutions Inc. grew EPS 125. 8% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EBS or BRKR or WAT or SIGA?
SIGA Technologies, Inc.
(SIGA) is the more profitable company, earning 24. 6% net margin versus -0. 3% for Bruker Corporation — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 6. 9% for BRKR. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EBS or BRKR or WAT or SIGA more undervalued right now?
On forward earnings alone, SIGA Technologies, Inc.
(SIGA) trades at 2. 8x forward P/E versus 24. 4x for Waters Corporation — 21. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EBS: 31. 4% to $12. 00.
08Which pays a better dividend — EBS or BRKR or WAT or SIGA?
In this comparison, SIGA (12.
7% yield), BRKR (0. 3% yield) pay a dividend. EBS, WAT do not pay a meaningful dividend and should not be held primarily for income.
09Is EBS or BRKR or WAT or SIGA better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Emergent BioSolutions Inc. (EBS) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, EBS: -76. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EBS and BRKR and WAT and SIGA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EBS is a small-cap deep-value stock; BRKR is a small-cap quality compounder stock; WAT is a mid-cap quality compounder stock; SIGA is a small-cap deep-value stock. SIGA pays a dividend while EBS, BRKR, WAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.